
    
      OBJECTIVES:

        -  Determine the efficacy of ixabepilone in patients with metastatic cisplatin-refractory
           germ cell tumors.

        -  Determine the safety of this drug in these patients.

      OUTLINE: Patients receive ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days
      in the absence of disease progression or unacceptable toxicity.

      PROJECTED ACCRUAL: A total of 10-29 patients will be accrued for this study within 1.3-4
      years.
    
  